<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02422719</url>
  </required_header>
  <id_info>
    <org_study_id>RAD-201501</org_study_id>
    <nct_id>NCT02422719</nct_id>
  </id_info>
  <brief_title>Radotinib as 3rd or Later Line Therapy in CP-CML</brief_title>
  <acronym>REVITAL</acronym>
  <official_title>Radotinib Efficacy and Safety Validation in Chronic Phase Chronic Myeloid Leukemia Patients Who Are Intolerant or Resistant to at Least Two Tyrosine Kinase Inhibitors As a Third or Subsequent Line Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ulsan University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ulsan University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether radotinib is effective and safe for
      patients with chronic myeloid leukemia, chronic phase who are intolerable or resistant to
      prior 2 or more tyrosine kinase inhibitors.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to determine whether radotinib 400mg bid is effective and safe
      for patients with chronic myeloid leukemia, chronic phase who are intolerable or resistant to
      prior 2 or more tyrosine kinase inhibitors. The primary end point is major cytogenetic
      response by 12 months.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2015</start_date>
  <completion_date type="Anticipated">March 2019</completion_date>
  <primary_completion_date type="Anticipated">March 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of Major cytogenetic response</measure>
    <time_frame>by 12 months after radotinib treatment</time_frame>
    <description>The rate of achieving major cytogenetic response [35% or less t(9;22) chromosome by conventional banding technique] in bone marrow by 12 months after radotinib treatment will be the primary end point.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of Major Molecular response (MR3.0) on each time point</measure>
    <time_frame>up to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number of Participants with Adverse Events</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">73</enrollment>
  <condition>Chronic Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>Radotinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Radotinib treatement single arm</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Radotinib</intervention_name>
    <description>Radotinib 400mg bid</description>
    <arm_group_label>Radotinib</arm_group_label>
    <other_name>Supect</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Chronic myeloid leukemia chronic phase (CP-CML) patients who are not tolerable or
             resistant to prior 2 or more tyrosine kinase inhibitors (TKIs).

          -  ECOG 0, 1, 2

          -  Patients who are agree and signed to informed consent.

        Exclusion Criteria:

          -  T315I mutation

          -  Prior exposure to radotinib

          -  Accelerated or blastic phase

          -  galactose intolerance, severe lactase deficiency or glucose galactose malabsorption

          -  Prior history of intensive cytotoxic chemotherapy except for TKIs

          -  Significant cardiac problem

          -  QTcF &gt; 450 msec

          -  Pancreatitis history prior to study enrollment

          -  Clinically significant malignant disease other than CML

          -  Pregnant or breast feeding woman
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hawk Kim, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ulsan University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hae Kyung Shin, R.N.</last_name>
    <phone>+82-52-230-1418</phone>
    <email>gem9771uuh@naver.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ulsan University Hospital</name>
      <address>
        <city>Ulsan</city>
        <zip>682714</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hawk Kim, M.D., Ph.D.</last_name>
      <phone>+82-52-250-8892</phone>
      <email>kimhawkmd@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Hawk Kim, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jae Cheol Jo, M.D., Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yoonsuk Choi, M.D., Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 5, 2015</study_first_submitted>
  <study_first_submitted_qc>April 20, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 21, 2015</study_first_posted>
  <last_update_submitted>May 10, 2016</last_update_submitted>
  <last_update_submitted_qc>May 10, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 11, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ulsan University Hospital</investigator_affiliation>
    <investigator_full_name>Hawk Kim</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Chronic myeloid leukemia</keyword>
  <keyword>Intolerance</keyword>
  <keyword>Resitance</keyword>
  <keyword>Radotinib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
    <mesh_term>Leukemia, Myeloid, Chronic-Phase</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

